Drug Approval | September 22, 2024
Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
India Business grew by 11.9% YoY to Rs. 1196.2 crore
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
European operations' revenue grew 58.4% to Rs 599.7 crore
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The company has entered into a three-year Deferred Prosecution Agreement
Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
Subscribe To Our Newsletter & Stay Updated
